Palvella Therapeutics (PVLA) Total Current Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Total Current Liabilities for 14 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 1.47% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (up 1.47% YoY), while the FY2025 annual figure was $11.3 million, down 5.77% from the prior year.
• Total Current Liabilities eased to $9.1 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $42.9 million in Q1 2023 and bottomed at $2.4 million in Q4 2023.
• Historically, Total Current Liabilities has averaged $19.6 million across 5 years, with a median of $11.3 million in 2025.
• Annual changes were most pronounced in 2023 — Total Current Liabilities plunged 93.55% — and 2024, when it soared 410.08%.
• Palvella Therapeutics' Total Current Liabilities stood at $36.6 million in 2022, then slumped by 93.55% to $2.4 million in 2023, then jumped by 410.08% to $12.0 million in 2024, then dropped by 5.77% to $11.3 million in 2025, then declined by 19.65% to $9.1 million in 2026.
• Business Quant data shows PVLA's Total Current Liabilities at $9.1 million in Q1 2026, $11.3 million in Q4 2025, and $10.3 million in Q3 2025.